Under a tenth of people that would benefit from GLP-1 drugs like Wegovy have access to them, states the World Health Organization as it issues its first recommendations on the medications.
With more than one billion individuals worldwide now living with obesity, it is advocating for increased and just access to these injectable treatments.
According to projections, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"The new guidance affirms that excess weight is a lifelong illness that can be managed with comprehensive and ongoing treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and logistical bottlenecks are significant obstacles to broad availability to the injections that can help people shift significant weight, says the body.
Skinny Jab Supply Crisis
Even in the current most optimistic scenario, the production of such drugs might only reach about 100 million people – less than 10% of those who need them, as stated by the health organization.
The advice urges countries and companies to expand access, through strategies such as patent sharing.
A patent on semaglutide – the main component of the drug Wegovy – is scheduled to end in several nations in 2026.
The Way Weight-Loss Injections Work
The injections mimick a biological compound to delay gastric emptying, curb appetite and increase feelings of fullness so people consume fewer calories.
Individuals usually begin shedding pounds after several weeks of commencing the weekly injections.
Research points to patients may put most of the weight back on after a year of halting the treatment, as their normal appetite come back.
Being carrying excess weight elevates your risk for contracting diseases, including type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity concerns individuals in all nations and was linked to 3.7 million fatalities worldwide in 2024, according to the health agency.
